Name (Synonyms) | Correlation | |
---|---|---|
drug763 | No intervention (survey study for medical doctors). Wiki | 1.00 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Although immune-inflammatory treatment is not routinely recommended to be used for SARS-CoV-2 pneumonia, according to the pathological findings of pulmonary oedema and hyaline membrane formation, timely and appropriate use of immune modulator together with ventilator support should be considered for the severe patients to prevent ARDS development. The sphingosine-1-phosphate receptor regulators Fingolimod (FTY720) is an effective immunology modulator which has been widely used in multiple sclerosis.The aim of this study was to determine whether the efficacy of fingolimod for a novel coronavirus disease (COVID-19).
Description: The lesion change on X-ray images from day 5 to baseline
Measure: The change of pneumonia severity on X-ray images Time: 5 day after fingolimod treatment